Latest News

Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.

At GOLD 2026, Alvar Agustí, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.

In the phase 2b VISTAS trial, volixibat improved sleep vs placebo in PSC with cholestatic pruritus, and itch responders saw greater fatigue and sleep gains.

Carla Nester, MD, discusses sustained proteinuria reduction and kidney function findings through 76 weeks of pegcetacoplan treatment.

In the phase 3 ELSPIRE trial, 85.3% of patients with PBC and ALP below 1.67× ULN reached ALP normalization on elafibranor at 52 weeks vs 23.3% on placebo.

Real-world data at AASLD 2026 show 37% to 55% of patients with MASH on resmetirom (Rezdiffra) improved liver stiffness by 25% or more at about one year.

In a 50-patient rhinovirus challenge study, a single nasal ETH47 dose cut peak viral load 40-fold, though the primary endpoint was not significant.

In the phase 3 IDEAL trial, 3 in 4 patients with PBC and ALP below 1.67× ULN reached ALP normalization on seladelpar at 52 weeks, compared with 16.1% on placebo.

October 2026 pulmonology highlights include FDA accelerated approval of Voceryq for recurrent respiratory papillomatosis and CHEST 2026 data.

October 2026 allergy news: FDA approvals for berotralstat pellets and remibrutinib, RAPIDe-3 data in HAE, alpha-gal syndrome, and Viaskin Peanut Patch.

Skin clearance and route of administration drove treatment choices among 202 patients with psoriasis in the ENCOMPASS-PP discrete choice experiment.

Alexa Kimball, MD, MPH, reviews tulisokibart safety in hidradenitis suppurativa, its potential in patients with IBD, and what phase 3 trials must answer.

In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.

In this segment of her interview, Kimball discusses phase 2b tulisokibart data in hidradenitis suppurativa and the rationale for targeting TL1A.

Oral prifemilast, a PDE4B-selective inhibitor, led to PASI 75 attainment in up to 57.4% of those with psoriasis at week 16 vs 10.8% with placebo.

Michael Wechsler, MD, discusses SWIFT/AGILE data showing 59% of patients in remission with depemokimab at year 1 maintained it at year 2.

October 2026 hepatology news includes FDA approval of bepirovirsen for hepatitis B, new ACLF criteria, ACG cirrhosis guidance, and MASH trial data.

KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.

Nephrology in October 2026: FDA approves ravulizumab for IgAN, plus ORIGIN 3, RAINIER, TELIGAN, and ATTACK data from Kidney Week.

HCPLive recaps October 2026 dermatology highlights, including data in hidradenitis suppurativa, atopic dermatitis, psoriasis, lupus, and alopecia areata.

The FDA updated the risankizumab label to make pretreatment TB evaluation a matter of clinical judgment across all indications, including psoriasis.

Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.

Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.